创新医疗(002173) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was CNY 201,344,535.99, a decrease of 1.40% compared to CNY 204,206,456.23 in the same period last year[4] - The net profit attributable to shareholders was a loss of CNY 2,977,863.39, representing a decline of 37.87% from a loss of CNY 2,159,886.00 in the previous year[4] - The company's net profit excluding non-recurring gains and losses was a loss of CNY 2,708,735.09, a decline of 876.63% from a profit of CNY 277,355.34 in the same period last year[4] - The weighted average return on equity was -0.16%, compared to -0.11% in the previous year, indicating a slight deterioration in profitability[4] - The company reported non-recurring losses totaling CNY 269,128.30 for the quarter, primarily due to other operating expenses[6] - The company's net loss for Q1 2024 was CNY 1,307,215,574.97, slightly increasing from CNY 1,304,237,711.58 in the previous quarter[13] - Operating profit was reported at -¥2,112,325.21, a decline from -¥224,986.20 in the previous period, reflecting a significant deterioration in operational performance[16] - Total revenue from operating activities was ¥182,904,706.98, down from ¥222,244,830.87, representing a decrease of about 17.7%[19] Cash Flow and Liquidity - The net cash flow from operating activities was negative CNY 17,663,752.00, a significant decrease of 242.76% compared to a positive cash flow of CNY 12,372,882.62 in the same period last year[4] - The company's cash and cash equivalents at the end of Q1 2024 were CNY 543,823,060.69, a decrease of 3.4% from CNY 563,083,485.71 at the beginning of the quarter[12] - The net cash flow from operating activities was -¥17,663,752.00, contrasting with a positive cash flow of ¥12,372,882.62 in the previous period[19] - Cash and cash equivalents at the end of the period totaled ¥529,951,281.78, an increase from ¥249,019,635.01 at the beginning of the period, showing a net increase of ¥280,931,646.77[19] - The company generated ¥304,563,287.72 from investment activities, significantly higher than the previous period's cash inflow of ¥215,000.00[19] - The net cash flow from financing activities was ¥10,452,995.48, compared to a negative cash flow of -¥6,065,486.72 in the previous period, indicating improved financing conditions[19] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,264,284,369.08, a decrease of 0.75% from CNY 2,281,472,772.53 at the end of the previous year[5] - The equity attributable to shareholders was CNY 1,867,174,252.09, down 0.16% from CNY 1,870,152,115.48 at the end of the previous year[5] - The total assets of the company at the end of Q1 2024 were CNY 2,264,284,369.08, a decrease of 0.8% from CNY 2,281,472,772.53 at the beginning of the quarter[13] - The total liabilities decreased to CNY 396,176,814.89, down 3.4% from CNY 410,385,658.35 at the beginning of the quarter[12] - The company's inventory decreased to CNY 37,726,419.22, down 9.9% from CNY 41,805,047.04 at the beginning of the quarter[12] - The company’s long-term equity investments decreased to CNY 14,345,628.32, down from CNY 15,219,218.88 at the beginning of the quarter, reflecting a decline of 5.7%[12] Earnings Per Share - The basic and diluted earnings per share were both negative CNY 0.0067, down 39.58% from negative CNY 0.0048 in the previous year[4] - Basic and diluted earnings per share were both reported at -¥0.0067, worsening from -¥0.0048 in the previous period[16] Other Information - The company has not disclosed any new product developments or market expansion strategies in this report[4] - The company has not undergone an audit for the first quarter report, which may affect the reliability of the financial data presented[21] - The company is set to implement new accounting standards starting in 2024, which may impact future financial reporting[20]